Marco Soster

University of Turin — Italy

Medicine · Health Sciences

12h-index777citations53works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(22), Pancreatic and Hepatic Oncology Research(21), Cancer Mechanisms and Therapy(12), Colorectal Cancer Treatments and Studies(10), PI3K/AKT/mTOR signaling in cancer(7)

Publications53 total

Hard-Shelled Glycol Chitosan Nanoparticles for Dual MRI/US Detection of Drug Delivery/Release: A Proof-of-Concept Study
Nanomaterials·2023· 8 citedOpen Access
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Data from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 6 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 3 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure Legend from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 4 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Data from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 3 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure Legend from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 6 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Serena Marchiò(37), Massimo Aglietta(29), Giuliana Cavalloni(22), Caterina Peraldo‐Neia(22), Francesco Leone(22), L. Gammaitoni(22), Ivana Sarotto(20), Giorgia Migliardi(20), Roberta Cavalli(11), Monica Argenziano(9), Federico Bussolino(8), Federica Capozzi(7), Giovanni Grignani(7), Ymera Pignochino(6), Carmine Dell’Aglio(6), Marco Basiricò(6), Loretta Gammaitoni(6), Dario Sangiolo(6), Piero Picci(6), Amina Khadjavi(6)